News

Disease manifestations that affect the brain, such as seizures, are relatively common with atypical hemolytic uremic syndrome (aHUS), as are digestive symptoms and heart-related problems, a study finds. The study, “Extrarenal manifestations of atypical hemolytic uremic syndrome: a systematic review and meta-analysis,” was published in Pediatric…

A 38-year-old woman in Portugal developed atypical hemolytic uremic syndrome (aHUS) despite showing no typical markers of the disease after she experienced gastrointestinal inflammation, according to a case report. “This case highlights the diagnostic and management challenges in aHUS when traditional disease markers are absent and emphasizes the importance…

Physicians in India described the case of atypical hemolytic uremic syndrome (aHUS) that manifested as loss of vision in one eye in a 30-year-old man. The patient was successfully managed with plasma therapy, because Soliris (eculizumab) was not available. “This is the first described case to our knowledge…

It may be safe for some adults with atypical hemolytic uremic syndrome (aHUS) to discontinue treatment once they’re clinically stable, but a decision depends on a complex group of factors, a study based on interviews with aHUS experts indicates. The patient’s health status, personal preferences, and access to close…

A weight-based regimen for administering Soliris (eculizumab) in people with atypical hemolytic uremic syndrome (aHUS) may allow patients to reach therapeutic levels of the medication with fewer infusions, saving time and money. “We suggest to introduce this dosing schedule as the standard of care to improve therapeutic success…

A 60-year-old man with atypical hemolytic uremic syndrome (aHUS) was successfully treated with Soliris (eculizumab) using a personalized dosing regimen based on clinical responses, according to a recent case study. Clinicians lowered the dose of the medication in parallel with clinical improvements and eventually discontinued treatment instead of…

Changes in platelet counts over the first two weeks on Ultomiris (ravulizumab-cwvz) in people with atypical hemolytic uremic syndrome (aHUS) may help predict the patients’ long-term response to such treatment, according to a new study. An analysis found that patients’ early platelet responses were linked to kidney improvements at…

Bone abnormalities were reported in two teenage girls who were on long-term treatment with Soliris (eculizumab) for atypical hemolytic uremic syndrome (aHUS) associated with a deficiency of the complement factor H (FH). Clinicians are unsure whether these previously undescribed bone abnormalities, including pain, deformities, and joint swelling, were…

Initial treatment with the drug Soliris (eculizumab) and immunosuppressive therapies was safe and effective for four children with severe atypical hemolytic uremic syndrome (aHUS) who had self-reactive antibodies against the complement factor H (FH). That’s according to a study from Argentina, which reported that all of the children…

Genetic testing may allow for the timely use of anti-complement therapy for atypical hemolytic uremic syndrome (aHUS), even if an infection with Shiga toxin-producing Escherichia coli (STEC), a trigger of the typical form of the disease, is present and initially upstages the correct diagnosis of aHUS. In a…